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Abstract To present the safety profile, the early healing
phase and the clinical outcomes at 24 weeks following
treatment of human intrabony defects with open flap
debridement (OFD) alone or with OFD and rhGDF-5
adsorbed onto a particulate β-tricalcium phosphate (β-
TCP) carrier. Twenty chronic periodontitis patients, each
with at least one tooth exhibiting a probing depth ≥6 mm
and an associated intrabony defect ≥4 mm entered the
study. Ten subjects (one defect/patient) were randomized to
receive OFD alone (control) and ten subjects OFD
combined with rhGDF-5/β-TCP. Blood samples were
collected at screening, and at weeks 2 and 24 to evaluate
routine hematology and clinical chemistry, rhGDF-5 plasma
levels, and antirhGDF-5 antibody formation. Plaque and
gingival indices, bleeding on probing, probing depth,
clinical attachment level, and radiographs were recorded
pre- and 24 weeks postsurgery. Comparable safety profiles
were found in the two treatment groups. Neither
antirhGDF-5 antibody formation nor relevant rhGDF-5
plasma levels were detected in any patient. At 6 months,
treatment with OFD+rhGDF-5/β-TCP resulted in higher
but statistically not significant PD reduction (3.7±1.2 vs.
3.1±1.8 mm; p=0.26) and CAL gain (3.2±1.7 vs. 1.7±
2.2 mm; p=0.14) compared to OFD alone. In the tested
concentration, the use of rhGDF-5/β-TCP appeared to be
safe and the material possesses a sound biological rationale.
Thus, further adequately powered, randomized controlled
clinical trials are warranted to confirm the clinical relevance
of this new approach in regenerative periodontal therapy.
rhGDF-5/β-TCP may represent a promising new techology
in regenerative periodontal therapy.
Keywords rhGDF-5 . Tissue engineering . Periodontal
regeneration . Clinical trial .β-TCP. Periodontal surgery
Introduction
Ultimately, periodontal regeneration aims at completely
restoring the periodontal attachment lost due to disease or
trauma including root cementum, periodontal ligament and
alveolar bone [1]. Recent studies using controlled preclin-
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ical models provide ample biologic evidence suggesting
that surgical protocols meeting critical requirements of
space provision, wound stabilization, and conditions favoring
primary intention healing may indeed support the reconstruc-
tion or regeneration of lost periodontal tissues [2, 3].
The 1996 American Academy of Periodontology World
Workshop [4] formulated the following criteria for a
treatment modality to be considered a periodontal regener-
ative procedure: 1) controlled histological animal studies
demonstrating formation of new cementum, periodontal
ligament, and alveolar bone; 2) controlled clinical studies
demonstrating gain of clinical attachment and alveolar
bone; and 3) human biopsies demonstrating formation of
new cementum, periodontal ligament, and alveolar bone
onto a previously “plaque-infected root surface”. Fulfilling
the first criterion, preclinical studies have pointed to a role
of growth/differentiation factor (GDF) -5, -6, and -7 in the
formation of the periodontal ligament [5, 6]. Recombinant
human GDF-5 (rhGDF-5) exhibits osteoinductive proper-
ties in vitro and in vivo [7]. Moreover, rhGDF-5 may
provide an environment conducive to periodontal wound
healing/regeneration affecting extracellular matrix metabo-
lism [8]. Still other studies have shown significant
periodontal regeneration in discriminating large animal
models following surgical implantation of both GDF-5
and GDF-7 [9–11].
An rhGDF-5/β-TCP device has been shown to enhance
periodontal regeneration in deep one-wall intrabony defects
in dogs [11]. The β-TCP carrier matrix exhibits a resorption
profile that apparently minimally interferes with bone
formation/remodeling and periodontal regeneration; β-
TCP, being biocompatible, resorbs and is replaced by bone
within weeks of implantation. Indeed, standalone β-TCP
technologies have been used for orthopedic and craniofacial
indications for more than 20 years as implantable bone
substitutes [12]. A recent study has shown that rhGDF-5/β-
TCP implanted in a rat calvarial defect model enhances
local bone formation [13].
Taken together, preclinical data suggest that rhGDF-5
may have a significant potential not only to induce/support
periodontal wound healing/regeneration but also to support
regeneration elsewhere in the axial and appendicular
skeleton [14]. Beyond preclinical studies, controlled clini-
cal pilot studies are needed to demonstrate clinical potential
and safety.
However, although rhGDF-5 appears to be promising for
enhancing periodontal regeneration, until now, it has not
been used in humans to treat periodontal defects and thus,
the safety and the clinical potential of the material are
unknown. Therefore, an exploratory study was specifically
designed to evaluate for the first time in humans the clinical
and histological outcomes following treatment of intrabony
defects with open flap debridement (OFD) alone or with
OFD and rhGDF-5 adsorbed onto a particulate β-tricalcium
phosphate (β-TCP) carrier.
The aim of this paper is to report on the study protocol,
safety profile, the early healing phase and the clinical
outcomes at 24 weeks while the histological outcomes are
presented and discussed in great detail in a subsequent
paper [15].
Materials and methods
Overall study design and plan
This pilot, phase IIa study used a stratified randomized,
open, controlled, two-arm, parallel group design. The
overall design and patient treatment allocation is summarized
in Fig. 1. The study was conducted at the Department of
Periodontology, Semmelweis University, Budapest, Hungary
between July 2007 and August 2008. The study protocol was
approved by the Hungarian National Institute of Pharmacy
and the Institutional Ethics Committee (application no.
32579/40/06) of the Semmelweis University, Budapest,
Hungary (TUKEB (RICSRE) no. 20/2007). All patients
received oral and written explanations of the research
protocol. Patients signed a consent form providing the
possibility of withdrawing from the study at any time. The
study was planned and conducted in compliance with the
Declaration of Helsinki of 1975 as revised in 2000, Good
Clinical Practice, and relevant local laws.
The total study duration was 175–182 days, in all ten
visits/patient. After screening, selected patients received
flap surgery (control) or flap surgery combined with
implantation of rhGDF-5/β-TCP at the qualified defect site
(Visit 2). They then returned for general and oral health
evaluations as well as professional tooth cleanings follow-
ing a set schedule (Visits 3 through 8). Blood samples were
collected at screening (Visit 1), and at weeks 2 and 24
(Visits 3 and 9) to evaluate routine hematology and clinical
chemistry, rhGDF-5 plasma levels, and antirhGDF-5 anti-
body formation.
Study population
Twenty Caucasian male and female patients, nonsmokers,
in good general health, volunteered to participate in this
study. They all exhibited advanced chronic periodontitis
with one deep intrabony defect located at a maxillary or
mandibular single-rooted tooth without root concavities/
furrows or at the mesial or distal aspect of a mandibular
molar without contacting teeth (Fig. 2). Mandibular incisors
and teeth with furcation involvements were excluded. Only
teeth with a probing depth ≥6 mm and an intrabony
component ≥4 mm as estimated from long cone parallel
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technique radiographs confirmed during surgery were
considered (Fig. 3). Moreover, the patients were expected
to meet oral hygiene standards encompassing full mouth
plaque and bleeding scores <20% after completion of basic
periodontal therapy [16, 17]. Each patient contributed one
tooth subject to the study treatment.
Main exclusion criteria were: a) women of childbearing
potential (FSH level <25 IU/L and menstrual bleeding
within 6 months)/pregnant or lactating women; b) tobacco
smoking; c) evidence of acute/chronic infection at the study
site; d) previous (<2 months)/current treatment with systemic
corticosteroids of a prednisone equivalent >5 mg/day; e)
Assessed for eligibility (n=21) 
Excluded  (n=1 ) 
Not meeting inclusion criteria (n=1)
Refused to participate (n=0) 
Other reasons (n=0) 
Analyzed (n=10) 
Excluded from analysis (n= 0) 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0) 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0)
Analyzed (n=10) 
Excluded from analysis (n=0) 
Enrollment 
Randomization 
Open flap debridement + 
MD05; PPD >6 mm (n=5) 
Received allocated 
intervention (n=5) 
Did not receive allocated 
intervention (n=0) 
Open flap debridement 
alone; PPD >6 mm (n=5)
Received allocated 
intervention (n=5) 
Did not receive allocated
intervention (n=0) 
Open flap debridement 
alone; PPD 4-6 mm (n=5) 
Received allocated 
intervention (n=5) 
Did not receive allocated 
intervention (n=0) 
Open flap debridement + 
MD05; PPD 4-6 mm (n=5) 
Received allocated 
intervention (n=5) 
Did not receive allocated 
intervention (n=0) 
Fig. 1 Patient flow chart/flow of participants through each stage
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previous (<12 months)/current treatment with drugs influenc-
ing bone metabolism including calcitonin, parathormone,
bisphosphonates, or fluoride; f) common contraindications
for periodontal surgery; and g) clinically relevant cardiovas-
cular, hepatic, and renal diseases. Due to the explorative type
of this study, a sample size of ten patients/group was selected.
rhGDF-5/β-TCP
The rhGDF-5/β-TCP device (Scil Technology GmbH,
Martinsried, Germany) comprises rhGDF-5 coated onto a
synthetic inorganic carrier, β-TCP, at a concentration of
500 μg/g β-TCP [13]. The β-TCP carrier consists of
particles of 500 to 1,000 μm in size with interconnecting
porosity. It comprises microporous and macroporous irreg-
ular granules of a phase purity >95%. The results of
porosity analysis have shown 43.7% microporosity, an
average pore diameter of 2.12 μm, and a totale pore area of
0.647 m2/g. The pore size of the macropores ranges
between 100 and 400 μm. The surface area is estimated at
1.2 m2/g [13]. The rhGDF-5 protein was coated onto the
carrier using Scil Technology’s proprietary technology. One
vial rhGDF-5/β-TCP contained 250 μg rhGDF-5 and 0.5 g
β-TCP [13]. In vitro analysis of the carrier used in this
study has shown that almost the entire amount of rhGDF-5
was released from the carrier within the first 7 days [18].
Randomization and treatment allocation
Randomization was performed using a computer-generated
randomization list via block randomization. Ten patients were
randomized to each treatment group. A separate random
scheme was generated. The investigators were masked to the
block length. The sponsor retained the randomization scheme
for control purposes. The investigator implemented the
predefined randomization by opening a randomization enve-
lope at the appointment for surgery (Visit 2). The randomiza-
tion code was opened only after the defect site was fully
prepared. The defects were randomly assigned to receive:
rhGDF-5/β-TCP following the manufacturer’s instructions
(test), or no additional treatment (control). All randomized
patients completed the study. Masking of treatment was not
applicable because the test group received rhGDF-5/β-TCP
whereas the control group was treated by periodontal surgery
only without additional treatment.
Fig. 3 Preoperative radiograph of the defect depicted in Fig. 2. A




Fig. 2 Flap surgery
plus rhGDF-5/β-TCP:
presurgery (a); intrasurgery
defect morphology (b); site
following implantation of
rhGDF-5/β-TCP (c); and site at
24 weeks (d)
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Safety assessment
Adverse events were monitored and recorded throughout
the study, as well as laboratory values, vital signs, and
physical status. Adverse events were coded using the
Medical Dictionary of Regulatory Activities (MedDRA)
[http://www.meddramsso.com/index.asp]. Summaries and
tabulations by severity and relationship to therapy were
based on the preferred terms and the primary system organ
classes (SOCs). Blood samples were collected at screening
(Visit 1), 2 weeks postsurgery (Visit 3), and prior to
conclusion of study (Visit 9) to determine laboratory values
(clinical chemistry, hematology), rhGDF-5 plasma levels,
and antirhGDF-5 antibodies.
The determination of rhGDF-5 in human plasma (EDTA)
samples was carried out by Elisa over a quantitation range
of 40 pg/ml to 1,250 pg/ml. A monoclonal antibody
specific for rhGDF-5 has been precoated on a 96-well
plate. Standards/QCs and samples were then pipetted into
the wells and any rhGDF-5 present was bound by the
immobilized antibody. After washing away any unbound
substances, a biotinylated monoclonal antibody specific for
rhGDF-5 was added to the wells. After a second washing
step, PolyHRP Streptavidin was added that bound to the
biotinylated antibody. After a third washing step, peroxi-
dase bound in the complex was visualized by TMB
(3,3′,5,5′-Tetramethylbenzidine) substrate solution. After
stopping the enzymatic reaction with sulfuric acid, the
intensity of the resulting color was determined at 450 nm.
The color intensity was proportional to the concentration of
rhGDF-5 in the sample.
Clinical assessment
Clinical outcomes were evaluated at baseline and at 24 weeks
postsurgery. Probing depth (PD), gingival recession (GR) and
clinical attachment level (CAL) were recorded using a
standard periodontal probe (UNC 15, Hu-Friedy, Chicago,
IL, USA). Intraoral radiographs were taken with the long cone
parallel technique at baseline and at 24 weeks postsurgery
(Figs. 3 and 4). However, due to the design of the study (i.e.
no grafting in the control group), the radiographs were not
evaluated for hard tissue changes.
Full mouth plaque and bleeding scores were recorded as
a percentage of total surfaces (four surfaces/tooth) with the
presence of plaque/bleeding on probing, respectively [16,
17]. One calibrated examiner, masked to the patients’
treatment protocol, performed all clinical recordings.
Pretreatment procedures
All patients had completed basic periodontal therapy
(individual oral hygiene instructions, supra- and subgingi-
val scaling and root planing) 8 weeks before screening. If
necessary, composite splinting of mobile teeth or eventually
fixed temporary restorations were completed.
Periodontal surgery
One experienced periodontist (PW) performed all surgeries
using local anesthesia, microsurgical instrumentation, and
appropriate magnification (Fig. 2). The surgical technique
was exactly the same for both the test and control groups. An
intracrevicular incision was made on the buccal and lingual
aspects of the surgical site. The flap was horizontally
extended to accommodate the defect location and configura-
tion, and ensured tension-free wound closure for primary
intention healing. Vertical releasing incisions were not used.
Granulation tissue removal and root instrumentation followed
elevation of the mucoperiosteal flaps. In the test group, six
patients received one-half vial rhGDF-5/β-TCP, one patient
received three-fourth vial rhGDF-5/β-TCP, and three patients
received one vial rhGDF-5/β-TCP (one vial rhGDF-5/β-TCP
contains 250 μg rhGDF-5 and 0.5 g β-TCP).
The mucoperiosteal flaps were then adapted and closed
using vertical or horizontal holding mattress sutures and
interrupted closing monofilament sutures (5/0 Dafilon; B.
Braun Melsungen AG, Melsungen Germany).
Postsurgical protocol
Postsurgery care included pain control (Nurofen, 200 mg,
3–4 times per day, Reckitt Benckiser, Slough, UK),
systemic (Augmentin 625 mg, GlaxoSmithKline, London,
UK London, UK; TID/7 days) and local (twice daily 0.2%
chlorhexidine; Curasept, Curadent International AG, Kriens,
Switzerland; rinses for 1 min, BID/4 weeks) antimicrobial
control. Antibiotic therapy started immediately after surgery.
Fig. 4 Postoperative radiograph of the defect depicted in Fig. 2
demonstrating defect fill at 24 weeks following surgery
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Sutures were removed at day 14. A series of control and
recall appointments were scheduled (biweekly, the first
6 weeks and then monthly until the end of the study)
including reinforcements of oral hygiene and professional
supragingival tooth cleaning.
Statistical analysis
The statistical analysis was conducted on an intent-to-treat
basis. All randomized patients with periodontal treatment
were included in the intent-to-treat population. Paired
sample t-test and Wilcoxon signed-rank test were used to
evaluate the impact of surgical interventions on the various
clinical parameters. Mann–Whitney U test (rank sum test)
was used to analyze differences among the various outcome
variables between treatment groups. No formal statistical
comparisons were made related to safety data.
Results
Patient demographics
Twenty-one patients were screened, 20 patients fulfilling
the inclusion criteria were randomized into two groups
of ten patients each (Fig. 1). One female patient was not
enrolled due to a low FSH level. Sixteen patients were
male and four, female. One female patient was randomized
to the control group and three to the rhGDF-5/β-TCP
group. All four female patients were postmenopausal.
Patient mean age was 48.8±10.6 years (range 33–
74 years). Age did not differ considerably between
treatment groups; median age was 50.0 years for both
groups. No dropouts occurred; all randomized patients
completed the study. The depth of the intrabony compo-
nent measured 6.7±2.8 mm in the test and 6.4±2.1 mm in
the control group, respectively (Tables 1 and 2).
Protocol deviations
A few patient visits occurred out of schedule. Blood
collection Visit 9 was completed 1–5 days early in five
patients. The biopsy procedure was performed 1–6 days
early or 1–3 days late in seven patients. Two patients
showed increased liver enzyme values at screening (ALT=
123 U/L, AST=107 U/L, GGT=142 U/L and ALT=101 U/L,
GGT=382U/L) that decreased to normal rangewithin 2weeks
(Visit 3) except GGT. No chronic liver disorder was reported
for either patient. One patient had insulin independent
diabetes (Hb1Ac=10.3% at screening), which was medically
controlled. None of these protocol deviations was considered
as major violation, and therefore, all patients were included in
the analyses.
Clinical characteristics
Full mouth plaque scores at Visit 2 averaged 7.3±6.7% for
the rhGDF-5/β-TCP and 8.9±4.8% for the control group;
and full mouth bleeding scores 11.2±4.1% for the rhGDF-
5/β-TCP and 12.7±5.4% for the control group. Probing
depths averaged 9.1±1.3 mm for the rhGDF-5/β-TCP and
9.2±2.3 mm for the control group. Clinical attachment level
averaged 12.2±1.5 mm for the rhGDF-5/β-TCP and 11.4±
3.5 mm for the control group.
The depth of the intrabony component as measured
during surgery measured 6.7±2.8 mm for the rhGDF-5/β-
TCP and 6.4±2.1 mm for the control group. The defects
displayed predominantly one- and two-wall configurations
(Tables 1 and 2).
Safety findings
The safety profile was comparable for patients receiving
rhGDF-5/β-TCP and control treatments. All abnormal
hematology and clinical chemistry values were judged as
clinically nonrelevant. Most common abnormal values were
GGT, followed by cholesterol, glucose, and white blood cell
count. Summary statistics did not show remarkable trends
from Visits 1 to 9 for any of the parameters analyzed. All
patients showed negative antirhGDF-5 antibody levels at
screening and Visits 3 and 9. No relevant rhGDF-5 plasma
levels were detected in any patient. Two patients, both
belonging to the rhGDF-5/β-TCP group showed rhGDF-5
plasma levels at screening (Visit 1) and postsurgery (Visits 3
and 9). One patient showed a plasma level of 46.7 pg/mL
rhGDF-5 at baseline (before implantation of rhGDF-5/β-
TCP) vs. 47.3 pg/mL at Visit 3, and 57.9 pg/mL at Visit 9.
The other patient showed a plasma level of 514 pg/mL
rhGDF-5 at baseline vs. 427 pg/mL at Visit 3, and
690 pg/mL at Visit 9. Due to the fact that the measured
rhGDF-5 plasma levels were already positive at the
baseline (before periodontal surgery) and did not
increase throughout the study, a causal relationship to
study medication can be excluded. For all other
samples, rhGDF-5 plasma levels were below the limit
of quantification (<40.0 pg/mL). It may, thus, be
anticipated that these results were false positive.
Adverse events
The overview of the adverse events is summarized in
Table 3. All adverse events were judged as mild or
moderate. Seventy-two events were reported; 54 in seven
patients from the rhGDF-5/β-TCP group (42 of which for
one single patient), and 18 in eight patients from the
control. As these were always single isolated events, one
adverse event was recorded for each episode. Most events
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were related to back pain (14 events) and headache (26
events). The following two events, in two different patients,
were judged to be possibly related to the regenerative
surgery but not necessarily related to the rhGDF-5: delayed
epithelialization and secondary healing of the interdental
papilla. Both were judged as mild and the patients recovered
without sequelae. No withdrawals due to an adverse event
were recorded. There were also no meaningful changes in
vital signs that would raise a safety concern.
Early wound healing events
Healing following surgeries progressed without major
complications. Primary intention healing was observed in
nine of ten patients in the rhGDF-5/β-TCP group, and in all
ten patients in the control group. One patient in the rhGDF-
5/β-TCP group experienced a slightly delayed epithelial-
ization of the interdental papilla resulting in complete
wound closure within 3 weeks.
Clinical outcomes
At 6 months, both treatments resulted in significant improve-
ments in terms of PD reduction and CAL gain compared to
baseline. Treatment with rhGDF-5/β-TCP resulted in higher,
but statistically not significant, PD reduction (3.7±1.2
vs. 3.1±1.8 mm; p=0.26) and CAL gain (3.2±1.7 vs. 1.7±
2.2 mm; p=0.14) compared to the control (Tables 1 and 2).
Discussion
This pilot randomized, controlled study is the first to
investigate the influence of GDF-5 on periodontal wound
Table 1 Patients, experimental teeth and surfaces, predominant defect
morphology, intrasurgery defect depth, initial pocket probing depth
(PD), clinical attachment level (CAL) and gingival recession (GR),
and changes in primary outcome variables (mm) for defect sites
receiving flap surgery combined with rhGDF-5/β-TCP
Patient Tooth Defect morphology Defect depth PD CAL GR ΔPD ΔCAL ΔGR
2 35 d 1-Wall 7 8 12 4 5 5 0
3 36 d 2-Wall 5 9 13 4 4 4 0
6 11 m 2-Wall 4 9 12 3 3 4 1
10 34 d Circumferential 5 9 11 2 4 3 −1
13 23p 1-Wall 11 11 15 4 6 6 0
14 23 d 2-Wall 11 11 12 1 4 3 −1
16 21 m 1-Wall 7 10 12 2 3 2 −1
17 21 m 1-Wall 4 7 10 3 2 0 −2
18 12 d 1-Wall 4 8 11 3 3 2 −1
19 45 d Circumferential 9 9 14 5 3 3 0
Mean±SD 6.7±2.8 9.1±1.3 12.2±1.5 3.1±.2 3.7±1.2 3.2±1.7 0.5±0.8
Table 2 Patients, experimental teeth and surfaces, predominant defect
morphology, intrasurgery defect depth, initial pocket probing depth
(PD), clinical attachment level (CAL) and gingival recession (GR),
and changes in primary outcome variables (mm) for defect sites
receiving flap surgery alone (control)
Patient Tooth Defect morphology Defect depth PD CAL GR ΔPD ΔCAL ΔGR
1 21m Circumferential 4 9 10 1 2 1 −1
4 12m 2-Wall 7 9 11 2 4 4 0
7 11m 1-Wall 7 12 13 1 6 4 −2
8 23m 1-Wall 5 8 9 1 3 1 −2
9 22m 1-Wall 5 8 10 2 3 0 −3
11 35d 2-Wall 5 7 8 1 1 −1 −2
12 44d 2-Wall 9 13 17 4 6 5 −1
15 34d 1-Wall 9 8 15 7 3 3 0
20 35d Circumferential 9 12 15 3 2 1 −1
21 11m 1-Wall 4 6 6 0 1 −1 −2
Mean±SD 6.4±2.1 9.2±2.3 11.4±3.5 2.2±2.0 3.1±1.8 1.7±2.2 1.4±1.0
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healing/regeneration in humans. An important finding
was that no safety concerns related to rhGDF-5/β-TCP
were encountered. Minor adverse events appeared to be
rather related to the surgical intervention than to the
used regenerative material, which did not seem to have
any negative influence upon the clinical outcomes. None
of the patients exhibited antiGDF-5 antibody levels
while elevated GDF-5 plasma levels were observed in
two patients receiving rhGDF-5/β-TCP. Overall labora-
tory evaluations failed to show any differences in the
safety profiles between the experimental and control
groups indicating that the rhGDF-5 formulation appears
safe.
Full mouth plaque and bleeding scores were main-
tained below 20% throughout the study, indicating an
optimal level of infection control. The observation that
healing was uneventful in both groups also indicates
that the rhGDF-5/β-TCP treatment was well tolerated
and did not elicit any local adverse reactions. In the test
group, special attention was paid not to overfill the
defects to avoid undue flap tension during wound
closure. Wound closure for primary intention healing
was maintained in all but one defect receiving rhGDF-5/
β-TCP showing slightly delayed epithelization of the
interdental papilla. Taken together, these clinical obser-
vations suggest that the rhGDF-5/β-TCP construct did
not appear to exert any detrimental influence on
periodontal wound healing/regeneration.
The clinical evaluation has indicated that both, open
flap debridement (OFD) combined with rhGDF-5/β-TCP
and OFD alone may result in statistically significant
probing depth reductions and clinical attachment gains
compared to baseline. Application of rhGDF-5/β-TCP
however, resulted in greater, although statistically not
significant, probing depth reduction and clinical attach-
ment gain compared to the control. These findings are
in agreement with those reported in previous preclinical
studies indicating a beneficial effect of GDF-5 on
periodontal wound healing/regeneration [10, 11, 19]. On
the other hand, the magnitude of clinical improvements
appeared to be in the range of those obtained with other
regenerative materials such as a recombinant platelet-
derived growth factor (rhPDGF BB) on a β-TCP carrier,
an enamel matrix protein derivative alone or guided tissue
regeneration either alone or combined with grafting
materials [20–27]. Furthermore, it is also important to
note that the results observed in the control group compare
favorably with previous studies evaluating treatment of
intrabony defects using flap surgery alone indicating that
substantial clinical improvements may be achieved with
this treatment modality if an optimal level of plaque
control is maintained [21–23, 26–28].
Another important issue, which should to be carefully
considered, is the interpretation of the findings. First of
all, due to its exploratory nature, the study does not
have an adequate statistical power to detect possible
differences between the groups. Secondly, a third
treatment group including the use of β-TCP alone
would have been needed to evaluate the possible
influence of the carrier on the clinical outomes. At this
point, it needs to be emphasized that the biological
rationale of using β-TCP alone for obtaining periodontal
regeneration is questionable since findings from human
histological studies have failed to demonstrate periodon-
tal regeneration following filling of intrabony defects
with β-TCP [29]. Therefore, β-TCP-based materials are
not recommended to be used alone, but mainly as carriers
for biologically active molecules such as the growth
factors used in the present study. On the other hand, it
should be kept in mind that the present study was not only
designed to evaluate the safety of rhGDF-5/β-TCP but
also the histological outcomes [15]. The histological
evaluation has indicated that treatment with OFD+
rhGDF-5/β-TCP resuted in 2- to 3-fold higher amount of
new bone and new cementum formation compared to OFD
alone without differences in frequency of root resorption
and ankylosis between the two groups [15]. The amount of
residual β-TCP carrier juxtaposed to the root surface in
the present group of biopsies was generally small (mean
8.4%), suggesting that this carrier would completely
degrade and/or resorb within a relatively short interval
[30]. In conclusion, the present findings indicate that in
the tested concentration the use of rhGDF-5/β-TCP
appeared to be safe and the material possesses a sound
biological rationale. Thus, further, adequately powered,
randomized controlled clinical trials are warranted to
confirm the clinical relevance of this new approach in
regenerative periodontal therapy.
Table 3 Overview of adverse events (AEs). No serious adverse events occurred
rhGDF-5/β-TCP Control
Number of patients with AEs, and number (AEs) 7 (54) 8 (18)
Number of patients with AEs possibly related to study medication, and number (AEs) 2 (2) n/a
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